S 735 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.
Summary
This bill reauthorizes and expands a federal sickle cell disease prevention and treatment program by increasing annual funding from $4.5 million to $8.2 million for fiscal years 2025 through 2029. It expands the program's focus to include prevention and treatment of sickle cell disease complications in addition to treatment of the disease itself. The bill allows the Secretary to make grants or enter into cooperative agreements with entities, in addition to contracts, and expresses Congress's support for further research on heritable blood disorders including sickle cell disease.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Sen. Scott, Tim [R-SC] (R-SC)
3 cosponsors
- Sen. Booker, Cory A. [D-NJ] (D-NJ)
- Sen. Ossoff, Jon [D-GA] (D-GA)
- Sen. Warnock, Raphael G. [D-GA] (D-GA)
Actions (2)
- Feb 26, 2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. · senate
- Feb 26, 2025 Introduced in Senate
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE SENATE OF THE UNITED STATES
February 26, 2025
Mr. Scott of South Carolina (for himself and Mr. Booker) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions
A BILL
To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025”.
SEC. 2. SICKLE CELL DISEASE PREVENTION AND TREATMENT.
(a) In General.—Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b-5(b)) is amended—
(1) in paragraph (1)(A)(iii), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”;
(2) in paragraph (2)(D), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”;
(3) in paragraph (3)—
(A) in subparagraph (A), by striking “enter into a contract with” and inserting “make a grant to, or enter into a contract or cooperative agreement with,”; and
(B) in subparagraph (B), in each of clauses (ii) and (iii), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”; and
(4) in paragraph (6), by striking “$4,455,000 for each of fiscal years 2019 through 2023” and inserting “$8,205,000 for each of fiscal years 2025 through 2029”.
(b) Sense of Congress.—It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease. <all>
Comments